Video Series

Providers speak to the importance of being knowledgeable of efficacy and safety data before prescribing biosimilars to patients.

Clinical and social challenges associated with biosimilars are discussed by key opinion leaders.

An overview of the HIMALAYA study and IMbrave150 trial are provided.

Medical experts discuss patient considerations when utilizing clinical pathways in HCC treatment.

David Fenstermacher, PhD, provides insights regarding key advancements and pipeline treatments for metastatic colorectal cancer.

The panelists examine a recent FDA approval that provides new opportunities for effective combination strategies in mCRC treatment.

Joseph M. Coney, MD, FACS, reviews best practices for improving adherence to treatment among patients with diabetic macular edema through comprehensive education on the disease and available therapies.

Experts discuss changes they foresee in the perioperative approach landscape for patients with NSCLC.

A panel deliberates post-neoadjuvant strategies and data requirements for optimizing immune checkpoint inhibitors in NSCLC neoadjuvant therapy.

Experts emphasize the crucial role of swift diagnostic testing, especially through liquid biopsies.

Specialists delve into strategies for monitoring treatment response and the importance of assessing symptoms during the initial three treatment cycles.

Russell P. Gollard, MD, FACP, discusses hemophilia patients in their plan, identifying these patients, and treatment with newer monoclonal factor products.

Financial and geographic disparities contributing to elevated risk for heart disease are explored.

Robert Groves, MD, leads a panel discussion surrounding risk factors related to heart disease.

Panelists explore opportunities for biosimilars to manage inflammatory conditions.

Experts explore current and future use of biosimilars in dermatology, gastroenterology, and rheumatology.

Benefits of clinical pathway implementation in HCC management are examined.

Ryan Haumschild, PharmD, MS, MBA, drives an expert discussion focused on challenges associated with clinical pathway utilization in treating patients with HCC.

Medical experts discuss treatment-related toxicity management strategies in mCRC.

Ben George, MD, and John L. Marshall, MD, analyze the use of targeted therapies as an alternative to chemotherapy in mCRC treatment.

In his closing thoughts, Dr Gordon discusses navigation of treatment resistance in DLBCL management.

The impact of collaborative care in DLBCL treatment is explored by a medical expert.

Joseph M. Coney, MD, FACS, discusses the challenges physicians encounter when treating diabetic macular edema and the impact of the disease on patients’ quality of life.

Experts deliberate on the optimal timing of chemoimmunotherapy and if it should be before or after surgery.

A panel discusses the role of neoadjuvant therapy in the current treatment approach for early stages of NSCLC.

Providers speak to the importance of encouraging patients to self-report adverse reactions and participate in shared decision making.

Experts address the impact of platinum shortages, 4-cycle platinum chemotherapy, and available treatments beyond platinum chemotherapy.

Expert panelists share final points of emphasis regarding treatment for CKD.